Press Releases

Date Title View
Toggle SummaryMarch 23, 2020 GenMark Awarded BARDA Grant for the Development of ePlex® RP2 Panel
CARLSBAD, Calif. , March 23, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has been awarded a grant from the Biomedical Advanced Research and Development Authority (BARDA), part
View HTML
Toggle SummaryMarch 19, 2020 GenMark Receives FDA Emergency Use Authorization for its ePlex® SARS-CoV-2 Test
COVID-19 diagnosis in under two hours now available globally in hospitals on company’s ePlex System Unique sample-to-answer capability enables near patient testing for the most critical patient populations CARLSBAD, Calif. , March 19, 2020 (GLOBE NEWSWIRE) --   GenMark Diagnostics, Inc.
View HTML
Toggle SummaryMarch 11, 2020 GenMark Diagnostics Announces Submission of Emergency Use Authorization for its ePlex® SARS-CoV-2 Test
CARLSBAD, Calif. , March 11, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced submission for an Emergency Use Authorization (EUA) to the U.S.
View HTML
Toggle SummaryMarch 2, 2020 GenMark Diagnostics Reports Fourth Quarter and Full Year 2019 Results
CARLSBAD, Calif. , March 02, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2019 .
View HTML
Toggle SummaryMarch 2, 2020 GenMark Diagnostics Announces Global Shipments of ePlex® RUO Test Kits Designed for SARS-CoV-2 Detection
CARLSBAD, Calif. , March 02, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the initial shipments of ePlex Research Use Only (RUO) test kits designed to detect the SARS-CoV-2 virus. 
View HTML
Toggle SummaryFebruary 18, 2020 GenMark Diagnostics to Participate in the Cowen Health Care Conference
CARLSBAD, Calif. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen Health Care Conference in Boston, Massachusetts
View HTML
Toggle SummaryFebruary 10, 2020 GenMark Diagnostics Schedules Fourth Quarter and Full Year 2019 Financial Results Conference Call for March 2, 2020
CARLSBAD, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Monday, March 2, 2020. Management will hold a conference call to review the company's
View HTML
Toggle SummaryFebruary 10, 2020 GenMark Diagnostics Announces CEO and Chairman Transition
CARLSBAD, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that Scott Mendel , Chief Operating Officer, has been appointed Interim President and Chief Executive
View HTML
Toggle SummaryJanuary 13, 2020 GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2019
CARLSBAD, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2019 .
View HTML
Toggle SummaryDecember 30, 2019 GenMark Diagnostics to Participate in the J.P. Morgan Healthcare Conference
CARLSBAD, Calif. , Dec. 30, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming J.P. Morgan Healthcare conference in San Francisco,
View HTML